Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017035267) METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/035267 International Application No.: PCT/US2016/048470
Publication Date: 02.03.2017 International Filing Date: 24.08.2016
IPC:
A61K 31/135 (2006.01) ,A61K 31/137 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
137
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
Applicants:
ZOGENIX INTERNATIONAL LIMITED [US/GB]; Siena Court Broadway Maidenhead Berkshire SL6 1NJ, GB
Inventors:
FARR, Stephen J.; US
GALER, Bradley S.; US
Agent:
BOZICEVIC, Karl; US
Priority Data:
62/209,09024.08.2015US
Title (EN) METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE
(FR) MÉTHODES DE TRAITEMENT DE SYNDROME DE LENNOX-GASTAUT À L'AIDE DE FENFLURAMINE
Abstract:
(EN) A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a preferred dose of less than about 2.0 to about 0.01 mg/kg/day.
(FR) L'invention concerne une méthode de traitement et/ou la prévention de symptômes du syndrome de Lennox-Gastaut (LGS), également connu sous le nom de syndrome de Lennox, chez un patient pour lequel le syndrome de Lennox a été précédemment diagnostiqué, par administration d'une dose efficace de fenfluramine ou de son sel de qualité pharmaceutique à ce patient. Des patients atteints du syndrome de Lennox sont traités avec une dose préférée inférieure à environ 2,0 à environ 0,01 mg/kg/jour.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)